Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD ...

The following is a summary of “Comparative Effectiveness of qSOFA, CURB-65, and PSI in Predicting Pneumonia Hospitalization ...

Since their policy announcement in 2019, becoming smokefree is a national priority for central government who set out their ...

Denham Thomas, from Hartlepool, saw his life drastically altered by Chronic Obstructive Pulmonary Disease, becoming dependent ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

In adults with undiagnosed respiratory symptoms, dyspnea impact was worse in those with PRISm vs undiagnosed asthma or COPD.

The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

A National Institute for Health and Care Research (NIHR) evidence collection brings together research on whether stratified care can help primary care teams manage long-term conditions. Stratified ...

Baxter International, Inc. BAX announced the launch of its next-generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis ...

(Yicai) Sept. 30 -- AstraZeneca will strengthen its commitment to researching chronic and rare diseases in China, driving ...